source
- FDA extends safety review of mifepristone into next year, report due by March 2027The FDA announced that its ongoing safety evaluation of mifepristone, the primary medication used for medical abortions, will not be completed until next year. The agency expects to finish the saf…
- Zealand and Roche report positive Phase 2 results for amylin drug petrelintide in obesity and diabetesZealand Pharma and Roche announced topline results from a Phase 2 trial of their amylin analogue petrelintide in patients with obesity and type 2 diabetes. The interim data showed that participant…